Skip to main content
| Hans-Günter Meyer-Thompson | Buprenorphin

How do individuals fare long-term after receiving long-acting, injectable formulations of buprenorphine for opioid use disorder?

How do individuals fare long-term after receiving long-acting, injectable formulations of buprenorphine for opioid use disorder?

Evidence has mounted regarding the short-term effectiveness of long-acting buprenorphine formulations for opioid use disorder, but knowledge about longer-term psychosocial and other health outcomes have been lacking. This paper reports 12-month outcomes from a study of individuals who had previously taken part in one of two, year-long, clinical trials of a long-acting, injectable formulation of buprenorphine for moderate to severe opioid use disorder. (RRI – Recovery Research Institute, USA, November 2020)

https://www.recoveryanswers.org/research-post/long-term-effects-long-acting-injectable-buprenorphine-opioid-use-disorder/